# Royalty Pharma plc (RPRX) FY2026 Q1 Balance Sheet

- Company: Royalty Pharma plc (RPRX)
- Period: As of 2026-03-31
- Filing: Q1 FY2026 10-Q, filed 2026-05-06, accession number 0001802768-26-000009
- Page: https://plicit.ai/financials/rprx/fy2026-q1-balance-sheet
- Chart image: https://plicit.ai/charts/rprx-fy2026-q1-balance-sheet-sankey.png

## Chart details

Balance sheet as of 2026-03-31. The chart shows assets, liabilities and equity at that date.

- **Assets**: 19,815,415,000 US dollars
- **Current assets**: 1,425,811,000 US dollars
- **Non-current assets**: 18,389,604,000 US dollars
- **Liabilities**: 9,878,582,000 US dollars
- **Current liabilities**: 535,682,000 US dollars
- **Non-current liabilities**: 9,342,900,000 US dollars
- **Equity**: 9,936,833,000 US dollars
- **Noncontrolling interest**: 3,048,287,000 US dollars. Included in consolidated equity; this amount is not added again.
- **Financial royalty assets**: 779,844,000 US dollars
- **Cash and cash equivalents**: 586,395,000 US dollars
- **Other royalty income receivable**: 27,511,000 US dollars
- **Available for sale debt securities**: 21,900,000 US dollars
- **Other current assets**: 10,161,000 US dollars
- **Financial royalty assets, net**: 16,542,353,000 US dollars
- **Goodwill**: 924,634,000 US dollars
- **Available for sale debt securities**: 406,800,000 US dollars
- **Equity method investments**: 265,697,000 US dollars
- **Equity securities**: 173,270,000 US dollars
- **Other assets**: 76,850,000 US dollars
- **Current portion of long-term debt**: 380,000,000 US dollars
- **Distributions payable to non-controlling interests**: 87,417,000 US dollars
- **Accounts payable and accrued liabilities**: 25,483,000 US dollars
- **Interest payable**: 25,302,000 US dollars
- **Other current liabilities**: 17,480,000 US dollars
- **Long-term debt**: 8,576,443,000 US dollars
- **Accrued compensation liabilities**: 648,672,000 US dollars
- **Other liabilities**: 117,785,000 US dollars
- **Additional paid-in capital**: 4,384,056,000 US dollars
- **Retained earnings**: 2,507,091,000 US dollars
- **Common stock - Class R Redeemable Shares**: 63,000 US dollars
- **Common stock - Class A Ordinary Shares**: 45,000 US dollars
- **Deferred shares, $0.000001 par value; issued and outstanding: 2026–427,355 and 2025–411,475**: 0 US dollars
- **Common stock - Class B Ordinary Shares**: 0 US dollars
- **Non-controlling interests**: 3,048,287,000 US dollars
- **Treasury interests**: negative 2,709,000 US dollars
- **Gross equity (calculated)**: 9,939,542,000 US dollars. Net equity plus the magnitudes of its negative contributions equals gross positive equity. The negative contributions enter this reconciliation as add-backs; their filed signs stay negative.

### Chart connections

- Assets equal liabilities plus consolidated equity. Consolidated equity includes noncontrolling interests when reported.
- Treasury shares and other negative equity contributions reduce equity.